

Flerie Invest AB has increased its holding in Toleranzia AB, whereby the limit for mandatory bidding has been exceeded.

THIS PRESS RELEASE DOES NOT CONSTITUTE A PUBLIC TENDER OFFER OR OTHERWISE AN OFFER TO ACQUIRE SHARES

Flerie Invest AB (“**Flerie Invest**”) has today acquired 446,009 shares in Toleranzia AB (“**Toleranzia**”). Flerie Invest’s total holding in Toleranzia following the acquisition amounts to 33,539,040 shares, comprising 30.4 per cent of the total amount of shares and votes of the company. The limit for mandatory bidding has thus been exceeded. Flerie Invest intends to revert with information about a possible public takeover bid regarding the remaining shares in Toleranzia within four weeks.

”The development in Toleranzia is progressing and we look forward to continued success for the company” says Thomas Elderred, Flerie Invest.

For further information, please contact:

Thomas Elderred, President or Cecilia Scheele, CFO

Both can be contacted at contact@flerie.com +46 (0)76 131 0127

This information was submitted for publication on 2 November 2022 at 19:00 CET.

About Flerie Invest AB

Flerie Invest is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of around 30 companies in Europe, Israel and the US. The focus is on enabling pioneering organisations operating in the drug development and services space to succeed by providing them with resources and expertise.

The portfolio includes a wide range of areas, including immuno-oncology, metabolic diseases and biologics development and manufacturing organisations, which have the potential to make a significant impact on health and wellbeing. Flerie Invest was founded in 2010 by Thomas Elderred, who also co-founded and built Recipharm to be one of the world’s top five pharmaceutical contract manufacturers. For more information, please visit www.flerie.com.